Evidence map›Paper›PMID 33278904›Full record

ArticleAlzheimer's research & therapy2020

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.

Steffi De Meyer, Jolien M Schaeverbeke, Inge M W Verberk, Benjamin Gille, Maxim De Schaepdryver, Emma S Luckett, Silvy Gabel, Rose Bruffaerts, Kimberley Mauroo, Elisabeth H Thijssen and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Combining plasma p-tauAlzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Steffi De MeyerLaboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, box 7003, Herestraat 49, 3000, Leuven, Belgium.
Jolien M SchaeverbekeLeuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Inge M W VerberkNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands.
Benjamin GilleLaboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, box 7003, Herestraat 49, 3000, Leuven, Belgium.
Maxim De SchaepdryverLaboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, box 7003, Herestraat 49, 3000, Leuven, Belgium.
Emma S LuckettLeuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Silvy GabelLeuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Rose BruffaertsLeuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Kimberley MaurooADx NeuroSciences, Ghent, Belgium.
Elisabeth H ThijssenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands.
Erik StoopsADx NeuroSciences, Ghent, Belgium.
Hugo M VandersticheleBiomarkable, Ghent, Belgium.
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands.
Rik VandenbergheLeuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Koen PoesenLaboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, box 7003, Herestraat 49, 3000, Leuven, Belgium. koen.poesen@uzleuven.be.
VIB-KU Leuven Center for Brain & Disease Research · BEADx NeuroSciences · BEAmsterdam University Medical Centers · NLKU Leuven · BEUniversitair Ziekenhuis Leuven · BEAmsterdam Neuroscience · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBlood-based amyloid biomarkers may provide a non-invasive, cost-effective and scalable manner for detecting cerebral amyloidosis in early disease stages.

methodsIn this prospective cross-sectional study, we quantified plasma Aβ

resultsELISA and SIMOA plasma Aβ

conclusionsELISA and SIMOA demonstrated equivalent performances in detecting cerebral amyloidosis through plasma Aβ

trial registrationEudraCT 2009-014475-45 (registered on 23 Sept 2009) and EudraCT 2013-004671-12 (registered on 20 May 2014, https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004671-12/BE ).

Indexed as

Alzheimer DiseaseAmyloidosisAgedAmyloid beta-PeptidesBiomarkersCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayHumansPeptide FragmentsProspective StudiesAmyloid beta-PeptidesBiomarkersPeptide FragmentsBiomarkersCerebral amyloidosisELISAImmunoassayPlasmaPreclinical Alzheimer’s diseasePrescreeningSIMOAβ-Amyloid

Identifiers

PMID33278904
PMCPMC7719262
OpenAlexW3111672229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.